000 | 01908 a2200529 4500 | ||
---|---|---|---|
005 | 20250514211853.0 | ||
264 | 0 | _c20050201 | |
008 | 200502s 0 0 jpn d | ||
022 | _a0917-5857 | ||
024 | 7 |
_aCliCa0405710718 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aTokumoto, Tadahiko | |
245 | 0 | 0 |
_a[Treatment of bone disease in chronic kidney disease and in renal transplant recipients under K/DOQI clinical practice guidelines]. _h[electronic resource] |
260 |
_bClinical calcium _cMay 2004 |
||
300 |
_a710-8 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Review | ||
650 | 0 | 4 | _aBone Density |
650 | 0 | 4 |
_aBone Diseases, Metabolic _xdiagnosis |
650 | 0 | 4 |
_aCalcitonin _xtherapeutic use |
650 | 0 | 4 | _aChronic Disease |
650 | 0 | 4 |
_aDiphosphonates _xtherapeutic use |
650 | 0 | 4 |
_aEpoxy Compounds _xtherapeutic use |
650 | 0 | 4 |
_aFurosemide _xtherapeutic use |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHyperparathyroidism, Secondary _xetiology |
650 | 0 | 4 |
_aIon Exchange Resins _xtherapeutic use |
650 | 0 | 4 |
_aKidney Diseases _xcomplications |
650 | 0 | 4 |
_aKidney Transplantation _xadverse effects |
650 | 0 | 4 | _aPamidronate |
650 | 0 | 4 | _aParathyroidectomy |
650 | 0 | 4 |
_aPhosphorus _xmetabolism |
650 | 0 | 4 |
_aPhosphorus, Dietary _xadministration & dosage |
650 | 0 | 4 | _aPolyamines |
650 | 0 | 4 |
_aPolyethylenes _xtherapeutic use |
650 | 0 | 4 | _aPractice Guidelines as Topic |
650 | 0 | 4 |
_aRenal Dialysis _xadverse effects |
650 | 0 | 4 | _aSevelamer |
650 | 0 | 4 |
_aTestosterone _xanalogs & derivatives |
650 | 0 | 4 | _aUnited States |
650 | 0 | 4 |
_aVitamin D _xadministration & dosage |
650 | 0 | 4 |
_aVitamin D Deficiency _xetiology |
700 | 1 | _aTanabe, Kazunari | |
700 | 1 | _aToma, Hiroshi | |
700 | 1 | _aAkiba, Takashi | |
773 | 0 |
_tClinical calcium _gvol. 14 _gno. 5 _gp. 710-8 |
|
856 | 4 | 0 |
_uhttps://doi.org/CliCa0405710718 _zAvailable from publisher's website |
999 |
_c15262149 _d15262149 |